Changes in the Liver Transplant Waiting List after Expanding to the ‘Up-to-Seven’ Criteria for Hepatocellular Carcinoma
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Singal, A.G.; Lampertico, P.; Nahon, P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J. Hepatol. 2020, 72, 250–261. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0168827819305197 (accessed on 10 November 2023). [CrossRef] [PubMed]
- Iwatsuki, S.; Starzl, T.E.; Sheahan, D.G.; Yokoyama, I.; Demetris, A.J.; Todo, S.; Tzakis, A.G.; van Thiel, D.H.; Carr, B.; Selby, R.; et al. Hepatic Resection Versus Transplantation for Hepatocellular Carcinoma. Ann. Surg. 1991, 214, 221–229. Available online: http://journals.lww.com/00000658-199109000-00005 (accessed on 10 November 2023). [CrossRef] [PubMed]
- Mazzaferro, V.; Regalia, E.; Doci, R.; Andreola, S.; Pulvirenti, A.; Bozzetti, F.; Montalto, F.; Ammatuna, M.; Morabito, A.; Gennari, L. Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. N. Engl. J. Med. 1996, 334, 693–700. Available online: http://www.nejm.org/doi/abs/10.1056/NEJM199603143341104 (accessed on 10 November 2023). [CrossRef] [PubMed]
- Galle, P.R.; Forner, A.; Llovet, J.M.; Mazzaferro, V.; Piscaglia, F.; Raoul, J.-L.; Schirmacher, P.; Vilgrain, V. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0168827818302150 (accessed on 10 November 2023). [CrossRef] [PubMed]
- Reig, M.; Forner, A.; Ávila, M.A.; Ayuso, C.; Mínguez, B.; Varela, M.; Bilbao, I.; Bilbao, J.I.; Burrel, M.; Bustamante, J.; et al. Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, AEC, SEOM, SERAM, SERVEI y SETH. Med. Clin. 2021, 156, 463.e1–463.e30. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0025775320307697 (accessed on 10 November 2023). [CrossRef] [PubMed]
- Rodríguez-Perálvarez, M.; Gómez-Bravo, M.Á.; Sánchez-Antolín, G.; De la Rosa, G.; Bilbao, I.; Colmenero, J. Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation. Transplantation 2021, 105, 602–607. Available online: https://journals.lww.com/10.1097/TP.0000000000003281 (accessed on 10 November 2023). [CrossRef] [PubMed]
- Mazzaferro, V.; Sposito, C.; Zhou, J.; Pinna, A.D.; De Carlis, L.; Fan, J.; Cescon, M.; Di Sandro, S.; Yi-feng, H.; Lauterio, A.; et al. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018, 154, 128–139. Available online: https://linkinghub.elsevier.com/retrieve/pii/S001650851736184X (accessed on 10 November 2023). [CrossRef]
- Yao, F. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33, 1394–1403. Available online: http://doi.wiley.com/10.1053/jhep.2001.24563 (accessed on 10 November 2023). [CrossRef]
- DuBay, D.; Sandroussi, C.; Sandhu, L.; Cleary, S.; Guba, M.; Cattral, M.S.; McGilvray, I.; Ghanekar, A.; Selzner, M.; Greig, P.D.; et al. Liver Transplantation for Advanced Hepatocellular Carcinoma Using Poor Tumor Differentiation on Biopsy as an Exclusion Criterion. Ann. Surg. 2011, 253, 166–172. Available online: https://journals.lww.com/00000658-201101000-00026 (accessed on 10 November 2023). [CrossRef]
- Sapisochin, G.; Goldaracena, N.; Laurence, J.M.; Dib, M.; Barbas, A.; Ghanekar, A.; Cleary, S.P.; Lilly, L.; Cattral, M.S.; Marquez, M.; et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology 2016, 64, 2077–2088. Available online: https://onlinelibrary.wiley.com/doi/10.1002/hep.2864 (accessed on 10 November 2023). [CrossRef]
- Reig, M.; Forner, A.; Rimola, J.; Ferrer-Fàbrega, J.; Burrel, M.; Garcia-Criado, Á.; Kelley, R.K.; Galle, P.R.; Mazzaferro, V.; Salem, R.; et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 2022, 76, 681–693. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0168827821022236 (accessed on 10 November 2023). [CrossRef] [PubMed]
- Martín-Delgado, M.C.; Martínez-Soba, F.; Masnou, N.; Pérez-Villares, J.M.; Pont, T.; Sánchez Carretero, M.J.; Velasco, J.; De la Calle, B.; Escudero, D.; Estébanez, B.; et al. Summary of Spanish recommendations on intensive care to facilitate organ donation. Am. J. Transplant. 2019, 19, 1782–1791. Available online: https://onlinelibrary.wiley.com/doi/10.1111/ajt.15253 (accessed on 10 November 2023). [CrossRef] [PubMed]
- Organización Nacional de Trasplantes. Registro Español de Trasplante Hepático. 1984–2019. 2019. Available online: http://www.ont.es/infesp/Registros/MEMORIA RETH 2019_GENERAL.pdf (accessed on 10 November 2023).
- Mazzaferro, V.; Llovet, J.M.; Miceli, R.; Bhoori, S.; Schiavo, M.; Mariani, L.; Camerini, T.; Roayaie, S.; Schwartz, M.E.; Grazi, G.L.; et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 2009, 10, 35–43. Available online: https://linkinghub.elsevier.com/retrieve/pii/S1470204508702845 (accessed on 10 November 2023). [CrossRef]
- EASL Clinical Practice Guidelines: Liver transplantation. J. Hepatol. 2016, 64, 433–485. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0168827815006777 (accessed on 10 November 2023). [CrossRef]
- Wiesner, R.; Edwards, E.; Freeman, R.; Harper, A.; Kim, R.; Kamath, P.; Kremers, W.; Lake, J.; Howard, T.; Merion, R.M.; et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124, 91–96. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0016508503500221 (accessed on 10 November 2023). [CrossRef]
- Kim, W.R.; Biggins, S.W.; Kremers, W.K.; Wiesner, R.H.; Kamath, P.S.; Benson, J.T.; Edwards, E.; Therneau, T.M. Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List. N. Engl. J. Med. 2008, 359, 1018–1026. Available online: http://www.nejm.org/doi/abs/10.1056/NEJMoa0801209 (accessed on 10 November 2023). [CrossRef]
- Edmondson, H.A.; Steiner, P.E. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 1954, 7, 462–503. Available online: https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(195405)7:3%3C462::AID-CNCR2820070308%3E3.0.CO;2-E (accessed on 10 November 2023). [CrossRef]
- Rodríguez-Perálvarez, M.; Luong, T.V.; Andreana, L.; Meyer, T.; Dhillon, A.P.; Burroughs, A.K. A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability. Ann. Surg. Oncol. 2013, 20, 325–339. Available online: http://link.springer.com/10.1245/s10434-012-2513-1 (accessed on 10 November 2023). [CrossRef]
- Lindemann, J.; Doyle, M.B.M. Expanding the Boundaries for Liver Transplantation for Hepatocellular Carcinoma. Surg. Clin. North Am. 2024, 104, 129–143. Available online: http://www.ncbi.nlm.nih.gov/pubmed/37953032 (accessed on 10 November 2023). [CrossRef]
- Yao, F.Y.; Xiao, L.; Bass, N.M.; Kerlan, R.; Ascher, N.L.; Roberts, J.P. Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF-Expanded Criteria Based on Preoperative Imaging. Am. J. Transplant. 2007, 7, 2587–2596. Available online: https://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2007.01965.x (accessed on 10 November 2023). [CrossRef]
- Herrero, J.I.; Sangro, B.; Quiroga, J.; Pardo, F.; Herraiz, M.; Cienfuegos, J.A.; Prieto, J. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl. 2001, 7, 631–636. Available online: http://www.ncbi.nlm.nih.gov/pubmed/11460231 (accessed on 10 November 2023). [CrossRef]
- Toniutto, P.; Fumolo, E.; Fornasiere, E.; Bitetto, D. Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review. J. Clin. Med. 2021, 10, 3932. Available online: http://www.ncbi.nlm.nih.gov/pubmed/34501381 (accessed on 10 November 2023). [CrossRef]
- de Ataide, E.C.; Garcia, M.; Mattosinho, T.J.A.P.; Almeida, J.R.S.; Escanhoela, C.A.F.; Boin, I.F.S.F. Predicting Survival After Liver Transplantation Using Up-to-Seven Criteria in Patients with Hepatocellular Carcinoma. Transplant. Proc. 2012, 44, 2438–2440. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0041134512007026 (accessed on 10 November 2023). [CrossRef]
- Amado, V.; Rodríguez-Perálvarez, M.; Ferrín, G.; De la Mata, M. Selecting patients with hepatocellular carcinoma for liver transplantation: Incorporating tumor biology criteria. J. Hepatocell. Carcinoma 2018, 6, 1–10. Available online: https://www.dovepress.com/selecting-patients-with-hepatocellular-carcinoma-for-liver-transplanta-peer-reviewed-article-JHC (accessed on 10 November 2023). [CrossRef]
- Yao, F.Y.; Kerlan, R.K.; Hirose, R.; Davern, T.J.; Bass, N.M.; Feng, S.; Peters, M.; Terrault, N.; Freise, C.E.; Ascher, N.L.; et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis. Hepatology 2008, 48, 819–827. Available online: https://onlinelibrary.wiley.com/doi/10.1002/hep.22412 (accessed on 10 November 2023). [CrossRef]
- Roberts, J.P.; Venook, A.; Kerlan, R.; Yao, F. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transplant. 2010, 16, 925–929. Available online: https://onlinelibrary.wiley.com/doi/10.1002/lt.22103 (accessed on 10 November 2023). [CrossRef]
- Otto, G.; Herber, S.; Heise, M.; Lohse, A.W.; Mönch, C.; Bittinger, F.; Hoppe-Lotichius, M.; Schuchmann, M.; Victor, A.; Pitton, M. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transplant. 2006, 12, 1260–1267. Available online: https://onlinelibrary.wiley.com/doi/10.1002/lt.20837 (accessed on 10 November 2023). [CrossRef]
- Cescon, M.; Cucchetti, A.; Ravaioli, M.; Pinna, A.D. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J. Hepatol. 2013, 58, 609–618. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0168827812007520 (accessed on 10 November 2023). [CrossRef]
- Pommergaard, H.-C.; Rostved, A.A.; Adam, R.; Thygesen, L.C.; Salizzoni, M.; Gómez Bravo, M.A.; Cherqui, D.; De Simone, P.; Boudjema, K.; Mazzaferro, V.; et al. Locoregional treatments before liver transplantation for hepatocellular carcinoma: A study from the European Liver Transplant Registry. Transpl. Int. 2018, 31, 531–539. Available online: https://onlinelibrary.wiley.com/doi/10.1111/tri.13123 (accessed on 10 November 2023). [CrossRef] [PubMed]
Pre-Expansion Period (2016–2018) | Post-Expansion Period (2019–2021) | p | |
---|---|---|---|
Age (years) | 57.6 ± 5.4 | 58.5 ± 4.9 | 0.38 |
Sex (men); n (%) | 62 (87.3%) | 40 (87%) | 0.95 |
Hepatitis B; n (%) | 12 (16.9%) | 3 (6.5%) | 0.1 |
Hepatitis C; n (%) | 44 (62%) | 27 (58.7%) | 0.72 |
Alcoholic liver disease; n (%) | 33 (46.5%) | 26 (56.5%) | 0.29 |
Portal Hypertension; n (%) | 63 (88.7%) | 42 (89.1%) | 0.95 |
Child-Pugh score | 5 (IQR 5–7) | 6 (IQR 5–7) | 0.49 |
MELD score | 9 (IQR 7–12) | 9 (IQR 8–13) | 0.17 |
Milan criteria out at inclusion (radiological), n (%) | 5 (7%) | 9 (19.6%) | 0.04 |
Number of nodules in the explanted liver, n (%) Single nodule Multinodular | 42 (59.2%) 29 (40.8%) | 31 (67.4%) 15 (32.6%) | 0.37 |
Main nodule diameter in the explanted liver (mm) | 28.2 ± 12.7 | 28.3 ± 11.2 | 0.97 |
Histological differentiation (moderate-poor); n (%) | 24 (58.5%) | 12 (48%) | 0.47 |
Microvascular invasion; n (%) | 17 (37.8%) | 12 (38.7%) | 0.93 |
Baseline AFP (ng/mL) | 4.9 (IQR 3.2–26) | 5.4 (IQR 3–17) | 0.99 |
Bridging locoregional therapy; n (%) | 61 (89.7%) | 37 (82.2%) | 0.25 |
Milan criteria out in the explanted liver, n (%) | 9 (12.5%) | 10 (21.1%) | 0.25 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zamora-Olaya, J.M.; Aparicio-Serrano, A.; Amado Torres, V.; Poyato González, A.; Montero, J.L.; Barrera Baena, P.; Sánchez Frías, M.; Ciria Bru, R.; Briceño Delgado, J.; De la Mata, M.; et al. Changes in the Liver Transplant Waiting List after Expanding to the ‘Up-to-Seven’ Criteria for Hepatocellular Carcinoma. J. Pers. Med. 2023, 13, 1670. https://doi.org/10.3390/jpm13121670
Zamora-Olaya JM, Aparicio-Serrano A, Amado Torres V, Poyato González A, Montero JL, Barrera Baena P, Sánchez Frías M, Ciria Bru R, Briceño Delgado J, De la Mata M, et al. Changes in the Liver Transplant Waiting List after Expanding to the ‘Up-to-Seven’ Criteria for Hepatocellular Carcinoma. Journal of Personalized Medicine. 2023; 13(12):1670. https://doi.org/10.3390/jpm13121670
Chicago/Turabian StyleZamora-Olaya, Javier Manuel, Ana Aparicio-Serrano, Víctor Amado Torres, Antonio Poyato González, José Luis Montero, Pilar Barrera Baena, Marina Sánchez Frías, Rubén Ciria Bru, Javier Briceño Delgado, Manuel De la Mata, and et al. 2023. "Changes in the Liver Transplant Waiting List after Expanding to the ‘Up-to-Seven’ Criteria for Hepatocellular Carcinoma" Journal of Personalized Medicine 13, no. 12: 1670. https://doi.org/10.3390/jpm13121670